GSK-2292767

CAS No. 1254036-66-2

GSK-2292767 ( GSK2292767; GSK-2292767; GSK 2292767 )

Catalog No. M11026 CAS No. 1254036-66-2

GSK-2269557 is a highly potent and selective inhibitor of PI3Kδ (pKi=10.1).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 119 Get Quote
10MG 189 Get Quote
25MG 416 Get Quote
50MG 706 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GSK-2292767
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK-2269557 is a highly potent and selective inhibitor of PI3Kδ (pKi=10.1).
  • Description
    GSK-2269557 is a highly potent and selective inhibitor of PI3Kδ (pKi=10.1); displays >1,000 fold selectivity versus others PI3K isoforms; inhibits both IFNγ and IL-2 production in a concentration-dependent manner, with pIC50 values of 8.7 and 8.5, respectively, in a human lung parenchyma assay; shows activity in rat acute OVA model of Th2-driven lung inflammation (ED50=35 ug/kg).COPD Phase 1 Clinical
  • Synonyms
    GSK2292767; GSK-2292767; GSK 2292767
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3Kδ
  • Research Area
    Inflammation/Immunology
  • Indication
    COPD

Chemical Information

  • CAS Number
    1254036-66-2
  • Formula Weight
    512.58
  • Molecular Formula
    C24H28N6O5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CS(=O)(NC1=CC(C2=CC3=C(C(C4=NC=C(CN5C[C@@H](C)O[C@@H](C)C5)O4)=C2)C=NN3)=CN=C1OC)=O
  • Chemical Name
    N-(5-(4-(5-(((2R,6S)-2,6-dimethylmorpholino)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Down K, et al. J Med Chem. 2015 Sep 24;58(18):7381-99.
molnova catalog
related products
  • Loureirin A

    Loureirin A has an inhibitory effect on platelet activation perhaps through an impairment of PI3K/Akt signaling.Loureirin A negatively affects agonist-induced platelet aggregation such as collagen collagen-related peptide (CRP) ADP and thrombin.

  • Tibolone

    Tibolone is an estrogen-like compound used for the treatment of the symptoms associated with menopausal transition (i.e., climacteric symptoms) and also for the treatment of osteoporosis.

  • Seletalisib

    Seletalisib (UCB-5857)is a potent, ATP-competitive, and selective PI3Kδ inhibitor with IC50 of 12 nM.